Ignite Creation Date:
2025-12-24 @ 5:07 PM
Ignite Modification Date:
2026-02-18 @ 11:51 PM
Study NCT ID:
NCT02587650
Status:
TERMINATED
Last Update Posted:
2020-01-27
First Post:
2015-10-23
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
Sponsor:
University of California, San Francisco
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | ALK Fusion Protein Expression | View |
| None | BRAF wt Allele | View |
| None | Invasive Skin Melanoma | View |
| None | MET Fusion Gene Positive | View |
| None | NRAS wt Allele | View |
| None | NTRK1 Fusion Positive | View |
| None | NTRK2 Fusion Positive | View |
| None | NTRK3 Fusion Positive | View |
| None | RET Fusion Positive | View |
| None | ROS1 Fusion Positive | View |
| None | Stage III Cutaneous Melanoma | View |
| None | Stage IIIA Cutaneous Melanoma | View |
| None | Stage IIIB Cutaneous Melanoma | View |
| None | Stage IIIC Cutaneous Melanoma | View |
| None | Stage IV Cutaneous Melanoma | View |
Keywords: